A Phase 1/2 study of Vadastuximb Talirine (SGN-CD33A) in

Project: Research project

Project Details

Description

A Phase 1/2 study of Vadastuximb Talirine (SGN-CD33A) in combination with Azacitidine in patients with previously untreated international prognostic scoring system (IPSS) intermediate-2 or high risk Myelodysplastic Syndrome (MDS)
StatusActive
Effective start/end date12/30/1512/30/21

Funding

  • Seattle Genetics, Inc.

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.